Research
27 papers- Central GABAA and GABAB receptor modulation of basal and stress-induced plasma interleukin-6 levels in mice.The Journal of pharmacology and experimental therapeutics · 1998
- Subtype specificity of gamma-aminobutyric acid type A receptor antagonism by clozapine.Naunyn-Schmiedeberg's archives of pharmacology · 1995
- GABAA receptor antagonism in the extended amygdala decreases ethanol self-administration in rats.European journal of pharmacology · 1995
- The differential antagonism by bicuculline and SR95531 of pentobarbitone-induced currents in cultured hippocampal neurons.European journal of pharmacology · 1996
- Evidence for a non-GABAergic action of quaternary salts of bicuculline on dopaminergic neurones.Neuropharmacology · 1997
via PubMed
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Gabazine (SR-95531) is a drug that acts as an antagonist at GABAA receptors. It is used in scientific research and has no role in medicine, as it would be expected to produce convulsions if used in humans.
Gabazine binds to the GABA recognition site of the receptor-channel complex and acts as an allosteric inhibitor of channel opening. The net effect is to reduce GABA-mediated synaptic inhibition by inhibiting chloride flux across the cell membrane, and thus inhibiting neuronal hyperpolarization. While phasic (synaptic) inhibition is gabazine-sensitive, tonic (extrasynaptic) inhibition is relatively gabazine-insensitive.
Excerpted from Wikipedia’s “gabazine bromide” article, available under the CC BY-SA 4.0 licence.